Additional Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    Paradigm Clinical Research Centers, LLC
    San Diego CA. 92108
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    UAB Lung Health Center
    Birmingham AL. 35233
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    The Lung Research Center, LLC
    Chesterfield MO. 63017
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    El Paso Pulmonary Association
    El Paso TX. 79902
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Temple Health - Oaks
    Phoenixville PA. 19460
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Temple University Hospital - Main Campus
    Philadelphia PA. 19140
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Washington
    Seattle WA. 98195
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Baylor College of Medicine
    Houston TX. 77030
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Utah
    Salt Lake City UT. 84108
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    The University of Kansas Medical Center
    Kansas City KS. 66160
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Johns Hopkins Asthma and Allergy Center
    Baltimore MD. 21205
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Research Institute McGill University Health Center
    Montreal QC. H4A 3J1
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Southern California
    Los Angeles CA. 90033
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Alabama at Birmingham
    Birmingham AL. 35205
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Maryland
    Baltimore MD. 21201
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Inova Healthcare
    Falls Church VA. 22042
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    El Paso Pulmonary Association, P.A.
    El Paso TX. 79902
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Intermountain Medical Center
    Murray UT. 84107
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Summit Health
    Bend OR. 97701
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Hannibal Regional Healthcare System, Inc.
    Hannibal MO. 63401
    View Details